Acute Myeloid Leukemia
University Health Network, Toronto
Ozmosis Research Inc.
This study aims to determine the safety and toxicity of incremental doses of Double Negative T (DNT) cells in human subjects with high risk acute myeloid leukemia (AML). DNT cells are mature T lymphocytes that comprise ~1% of white blood cells in humans. Injection of DNTs from healthy donors has been demonstrated to be effective against AML cells. DNT cells will be collected from healthy volunteers and injected into patients.
- Biological: DNT cellsDNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
|Ages eligible for Study||18 Years and older|
|Genders eligible for Study||All|
|Accepts Healthy Volunteers||Accepts Healthy Volunteers|
- Princess Margaret Cancer Centrenot yet recruitingToronto, Ontario, Canada, M5G2M9
not yet recruiting
28 February, 2017
06 February, 2017